[Use of triptorelin in the medical treatment of uterine myoma].
Following the introduction of GnRH analogue drugs the medical treatment of uterine myomatosis has been proposed. The use of these compounds in fact causes a reduction in mean plasma levels of 17-beta-estradiol which is reflected in the target tissue of myomas. Using this hormone-dependence as a starting Tryptoreline point, the study examined the volumetric changes induced by LH-RH agonist analogue, Tryptoreline, administered to a group of 15 selected patients. The results are encouraging: in all cases there was a marked reduction of tumour volume ranging between 30 and 40%. The therapeutic effect, however, gradually wore off following the suspension of treatment. For this reason, the use of this analogue should be reserved for premenopausal or younger patients for the treatment of menometrorrhagic episodes, or as a preoperative therapy in order to limit blood loss during surgery.
Palagiano
A
A
Clinica Ostetrica e Ginecologica, Facoltà di Medicina e Chirugia, II Università degli Studi di Napoli.
Trotta
C
C
Izzo
A
A
Ragucci
N
N
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D016063:Blood Loss, Surgical / Q000517:prevention & control; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D008875:Middle Aged; D011300:Preoperative Care; D012074:Remission Induction; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D017329:Triptorelin Pamoate
L'impiego della triptorelina nella terapia medica dei miomi uterini.